Phase 3 IMbrave150 Trial in Patients with Unresectable Hepatocellular Carcinoma: 2021 Update

home / investigator-perspectives / phase-3-imbrave150-trial-in-patients-with-unresectable-hepatocellular-carcinoma-2021-update

Expert reflections on the optimal identification and management of unresectable hepatocellular carcinoma given recent updates from the IMbrave150 trial.

EP. 1: Approaching the Identification and Management of HCC

Richard D. Kim, MD

August 13th 2021

Expert Richard Kim, MD, reflects on the nature of HCC, particularly the challenges inherent in diagnosis and management.

Watch

EP. 2: Unresectable HCC: Selecting the Optimal Frontline Therapy

Richard D. Kim, MD

August 17th 2021

A comprehensive overview of the frontline treatment landscape for patients with unresectable HCC, including those who present with contraindications to standard-of-care therapy.

Watch

EP. 3: Advice on Molecular Testing and Sequencing in Unresectable HCC

Richard D. Kim, MD

August 17th 2021

A brief synopsis on optimal sequencing strategies for patients who have been diagnosed with unresectable hepatocellular carcinoma.

Watch

EP. 4: IMbrave150: Frontline Atezolizumab + Bevacizumab in Unresectable HCC

Richard D. Kim, MD

August 17th 2021

Richard Kim, MD, shares insight on positive results from IMbrave150, which tested the frontline combination of atezolizumab and bevacizumab in patients with unresectable HCC.

Watch

EP. 5: Looking Toward the Future Management of Unresectable HCC

Richard D. Kim, MD

August 17th 2021

Considerations for ongoing clinical trials that may shape the future treatment landscape of unresectable hepatocellular carcinoma.

Watch